

Balaxi Pharmaceuticals Limited

To
Listing Department,
National Stock Exchange of India Limited.
Exchange Plaza, Plot No C/1, G Block, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

29th October, 2021

Stock Code: **BALAXI**

Sub: Intimation under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Newspaper clippings published on 29th October, 2021, in Business Standard (English) and Nava Telangana (Regional(Telugu) Edition) regarding the un-audited Standalone and Consolidated financial results of the Company for the 2nd quarter and half year ended 30th September, 2021.

The above information is also available on the website of the Company at www.balaxipharma.in

This is for your information and record.

Yours Faithfully,
For **Balaxi Pharmaceuticals Limited**,


Chinta Shalini
Company Secretary



Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)

Balaxi Pharmaceuticals Limited

Registered Office: 2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India- 500096.
 CIN: L25191TG1942PLC121598
 Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in
 (Formerly known as Balaxi Ventures Limited)

Extract of Unaudited Standalone and Consolidated Financial Results for The Quarter and Half Year Ended 30th September 2021

(₹ in Lakhs, unless specified)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter Ended 30/09/2021 Unaudited	Half Year Ended 30/09/2021 Unaudited	Quarter Ended 30/09/2020 Unaudited	Quarter Ended 30/09/2021 Unaudited	Half Year Ended 30/09/2021 Unaudited	Quarter Ended 30/09/2020 Unaudited
1.	Total Income from Operations	3,351.16	6,289.20	2,220.94	7,022.97	12,856.50	6,032.91
2.	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	541.19	1,134.60	569.01	1,403.28	2,652.39	1,180.61
3.	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	541.19	1,134.60	569.01	1,403.28	2,652.39	1,180.61
4.	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	403.43	846.68	426.32	1,205.41	2,276.78	1,011.53
5.	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	403.43	846.68	426.32	1,217.27	2,371.89	1,006.63
6.	Paid-up Equity Share Capital [Face value of Rs. 10 each]	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
7.	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year		3,324.56			5,497.98	
8.	Earnings Per Share (of Rs. 10/- each) (not annualised)						
	1. Basic (amount in Rs.)	4.03	8.47	4.26	12.05	22.77	10.12
	2. Diluted (amount in Rs.)	-4.03	8.47	4.26	12.05	22.77	10.12

Notes:

- a) The above is an extract of the detailed format of quarter and half year ended 30th September 2021. Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.
- b) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 28th October 2021 and have been subjected to Limited Review by the Statutory Auditors of the Company. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

Place: Hyderabad

Date: 28th October 2021

For and on behalf of Board of Directors,
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
 Managing Director



Maral Overseas Limited



Un-audited Financial Results for the quarter and half year ended 30th September, 2021

(₹ in Lakhs)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
Total Income from Operation (Net)	28496	22787	16910	51283	23749	63984
Net Profit/(Loss) for the period (before tax, Exceptional and / or Extra ordinary items)	2690	2179	373	4869	(1116)	2087
Net Profit for the period before tax (after Exceptional and/or Extra ordinary Items)	2690	2179	373	4869	(1116)	2087
Net Profit for the period after tax (after Exceptional and/or Extra ordinary Items)	1991	2042	371	4032	(1118)	1253
Total Comprehensive income for the period (Comprising profit/Loss for the period (after tax) and other comprehensive income (after tax))	2267	1936	394	4202	(948)	1390
Equity Share Capital	4150.80	4150.80	4150.80	4150.80	4150.80	4150.80
Reserves (excluding Revaluation Reserve as shown in the Balance sheet of the previous year)						5614

